Coherus BioSciences (CHRS) Reports Q4 Loss of $1.72/Share
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.26 -3.08%
EPS Growth %: +39.4%
Financial Fact:
Income/(loss) from operations: 27.38M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: +39.4%
Financial Fact:
Income/(loss) from operations: 27.38M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($1.72), versus ($1.56) reported last year. Revenue for the quarter came in at $14.07 million, versus $6.87 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
- TD Cowen on Alaska Air (ALK): 'Can Alaska ReAccelerate?'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
